Abstract
Between July 1979 and December 1981, 43 patients with metastatic germ-cell tumours (36 testicular non-seminomas and 7 testicular seminomas) were treated with 2-6 cycles of bleomycin, etoposide and cis-platin (BEP). Forty (93%) are alive, 37 (86%) with no evidence of disease. Of 36 men with testicular non-seminoma 30 (83.3%) are alive and disease-free at 8-38 months (median 17.0 months). In the latter group 25/28 (89.3%) who had had no prior irradiation are alive and disease-free. Fourteen non-seminoma patients had small volume metastases and 13 are in complete remission, as are 12/14 patients with bulky disease. All 7 patients with advanced seminoma are alive and disease-free. It is concluded that BEP is a well tolerated and effective first line treatment for patients with metastatic germ-cell tumours.
Full text
PDFSelected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bremer K., Niederle N., Krischke W., Higi M., Scheulen M. E., Schmidt C. G., Seeber S. Etoposide and etoposide-ifosfamide therapy for refractory testicular tumors. Cancer Treat Rev. 1982 Jun;9 (Suppl):79–84. doi: 10.1016/s0305-7372(82)80083-2. [DOI] [PubMed] [Google Scholar]
- Cavalli F., Klepp O., Renard J., Röhrt M., Alberto P. A phase II study of oral VP-16-213 in non-seminomatous testicular cancer. Eur J Cancer. 1981 Feb;17(2):245–249. doi: 10.1016/0014-2964(81)90043-8. [DOI] [PubMed] [Google Scholar]
- Einhorn L. H., Donohue J. P. Combination chemotherapy in disseminated testicular cancer: the Indiana University experience. Semin Oncol. 1979 Mar;6(1):87–93. [PubMed] [Google Scholar]
- Einhorn L. H., Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977 Sep;87(3):293–298. doi: 10.7326/0003-4819-87-3-293. [DOI] [PubMed] [Google Scholar]
- Einhorn L. H., Williams S. D. Chemotherapy of disseminated testicular cancer. A random prospective study. Cancer. 1980 Sep 15;46(6):1339–1344. doi: 10.1002/1097-0142(19800915)46:6<1339::aid-cncr2820460607>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
- Fitzharris B. M., Kaye S. B., Saverymuttu S., Newlands E. S., Barrett A., Peckham M. J., McElwain T. J. VP16-213 as a single agent in advanced testicular tumors. Eur J Cancer. 1980 Sep;16(9):1193–1197. doi: 10.1016/0014-2964(80)90178-4. [DOI] [PubMed] [Google Scholar]
- Issell B. F., Crooke S. T. Etoposide (VP-16-213). Cancer Treat Rev. 1979 Jun;6(2):107–124. doi: 10.1016/s0305-7372(79)80045-6. [DOI] [PubMed] [Google Scholar]
- Newlands E. S., Bagshawe K. D. Epipodophylin derivative (VP 16-23) in malignant teratomas and choriocarcinomas. Lancet. 1977 Jul 9;2(8028):87–87. doi: 10.1016/s0140-6736(77)90088-5. [DOI] [PubMed] [Google Scholar]
- Williams S. D., Einhorn L. H., Greco F. A., Oldham R., Fletcher R. VP-16-213 salvage therapy for refractory germinal neoplasms. Cancer. 1980 Nov 15;46(10):2154–2158. doi: 10.1002/1097-0142(19801115)46:10<2154::aid-cncr2820461008>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]